MedTech Dive February 16, 2024
Roche and Quest Diagnostics were among those to invest in the company’s development of early cancer detection blood tests.
Dive Brief:
- Freenome has raised $254 million to support the development of single- and multi-cancer early detection blood tests, the company said Thursday.
- The investment comes two months after Freenome started a second registrational study, adding a lung cancer trial to a colorectal cancer program that was scheduled to end in December 2023.
- Roche, which owns cancer test company Foundation Medicine, led the financing round. Quest Diagnostics also participated and said it is looking forward to “collaborating with Freenome to advance the potential of their breakthrough multiomics technology for multi-cancer screening.”
Dive Insight:
Freenome, like other liquid biopsy developers...
Today's Sponsors
Today's Sponsor